

GLOBAL WHOLEHEALTH PARTNERS CORP

FORM 8-K (Current report filing)

Filed 08/05/20 for the Period Ending 08/03/20

Address	2227 AVENIDA OLIVA SAN CLEMENTE, CA, 92673
Telephone	(714) 392-4112
CIK	0001598308
Symbol	GWHP
SIC Code	2835 - In Vitro and In Vivo Diagnostic Substances
Industry	Healthcare Facilities & Services
Sector	Healthcare
Fiscal Year	06/30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 3, 2020

GLOBAL WHOLEHEALTH PARTNERS CORPORATION
(Exact name of registrant as specified in its charter)

Nevada
(State or other jurisdiction
of incorporation)

000-56035
(Commission File Number)

46-2316220
(IRS Employer
Identification No.)

2227 Avenida Oliva
San Clemente, CA
(Address of Principal Executive Offices)

92673
(Zip Code)

Registrant's telephone number, including area code (714) 392-9752

N/A
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Section 8 - Other Events

Item 8.01 Other Events.

On August 3, 2020, Global Wholehealth Partners Corporation (the “Company”) received a Letter of Authorization from Healgen Scientific Limited which authorizes the Company to sell Healgen Scientific Limited’s SARS-COV-2 IgG/IgM Antibody Whole Blood, Serum and Plasma. As of May 29, 2020, Healgen Scientific Limited has received Emergency Use Authorization for the Healgen COVID-19 IgG/IgM rapid test cassette (WB/S/P) from the Food and Drug Administration.

The Letter of Authorization from Healgen Scientific Limited is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by this reference.

Section 9 – Financial Statement and Exhibits

Item 9.01 Financial Statements and Exhibits.

<u>Exhibit No.</u>	<u>Document</u>	<u>Location</u>
99.1	Healgen Scientific Limited Letter of Authorization	Filed Herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GLOBAL WHOLEHEALTH PARTNERS CORPORATION
(Registrant)

Date: August 5, 2020

By: /s/ Charles Strongo
Charles Strongo
Chief Executive Officer



Healgen Scientific Limited

3818 Fuqua St, Houston, TX 77047

Phone: 713.733.8088

Fax: 713.733.8848

Website: www.healgen.com

Email: healgensales@healgen.us

This letter gives Global Wholehealth Partners Corp the Authorization to sell Healgen Scientific SARS-COV-2 IgG/IgM Antibody Whole Blood, Serum and Plasma for as of May 29, 2020 the U.S. Food and Drug Administration (FDA) had provided Emergency Use Authorization (EUA) for the Healgen COVID-19 IgG/IgM rapid test cassette (WB/S/P) serology test.

A handwritten signature in black ink, appearing to read "Jianqiu Fang". The signature is written in a cursive, flowing style.

Sincerely,
Jianqiu Fang
CEO

